Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue History
Annual and quarterly revenue from 2008 to present
TNXP Revenue Over Time (2008–2025)
TNXP Revenue Growth History
2 of 2 years with positive growth- FY2008 revenue growth
- N/A
- FY2009 revenue growth
- N/A
- FY2010 revenue growth
- N/A
- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- +29.9%
- FY2025 revenue growth
- +29.8%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $6.9M | +183.2% |
| Q4 2025 | $5.4M | +108.8% |
| Q3 2025 | $3.3M | +16.6% |
| Q2 2025 | $2.0M | -9.5% |
| Q1 2025 | $2.4M | -2.1% |
| Q4 2024 | $2.6M | -31.7% |
| Q3 2024 | $2.8M | -29.3% |
| Q2 2024 | $2.2M | — |
Multi-year avg. share of annual revenue by fiscal quarter
TNXP Revenue Analysis (2008–2025)
Current Revenue & Growth
As of June 29, 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) generated trailing twelve-month (TTM) revenue of $17.6 million, reflecting explosive growth of +183.2% year-over-year. The most recent quarter (Q1 2026) recorded $6.9 million in revenue, up 27.6% sequentially.
Historical Growth Trajectory
TNXP's historical revenue data shows various trends over time. Tonix Pharmaceuticals Holding Corp.'s highest annual revenue of $13.1 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including AXSM (+63.9% YoY), INVA (+13.6% YoY), and SUPN (+16.3% YoY) — TNXP has outperformed the peer group in revenue growth. Compare TNXP vs AXSM →
TNXP Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TNXPCurrent | $18M | +183.2% | - | -959.1% | |
 AXSM | $638M | +63.9% | - | -26.5% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 CORT | $761M | +12.2% | +16.6% | 5.9% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% |
TNXP Historical Revenue Data (2008–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $13.1M | +29.8% | $4.5M | 34.7% | $-125,703,000 | -959.1% |
| 2024 | $10.1M | +29.9% | $2.3M | 23.1% | $-136,701,000 | -1354.3% |
| 2023 | $7.8M | - | $3.0M | 39.0% | $-118,380,000 | -1523.9% |
| 2022 | $0 | - | $0 | - | $-112,091,000 | - |
| 2021 | $0 | - | $0 | - | $-92,312,000 | - |
| 2020 | $0 | - | $-27,000 | - | $-50,511,000 | - |
| 2019 | $0 | - | $0 | - | $-28,828,000 | - |
| 2018 | $0 | - | $-26,322,000 | - | $-26,322,000 | - |
| 2017 | $0 | - | $-21,291,000 | - | $-21,291,000 | - |
| 2016 | $0 | - | $-38,969,000 | - | $-38,969,000 | - |
| 2015 | $0 | - | $-48,162,000 | - | $-48,162,000 | - |
| 2014 | $0 | - | $-27,656,000 | - | $-27,656,000 | - |
| 2013 | $0 | - | $-10,888,000 | - | $-10,888,000 | - |
| 2012 | $0 | - | $-6,661,410 | - | $-6,661,410 | - |
| 2011 | $0 | - | $-3,378,528 | - | $-3,378,528 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TNXP — Frequently Asked Questions
Quick answers to the most common questions about buying TNXP stock.
Is TNXP's revenue growth accelerating or slowing?
TNXP revenue growth is accelerating. TTM revenue reached $18M, up +183.2% year-over-year — ahead of the 5-year CAGR of N/A. This indicates the business is expanding faster than its historical baseline.
What is TNXP's revenue history from 2008 to 2026?
Tonix Pharmaceuticals Holding Corp. (TNXP) revenue history spans 2008 to 2026. TTM revenue as of 2026 is $18M, growing at +183.2% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is TNXP's long-term revenue growth rate (CAGR)?
Tonix Pharmaceuticals Holding Corp.'s 5-year revenue CAGR of N/A reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +183.2% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for TNXP.
Why does TNXP's quarterly revenue fluctuate?
TNXP quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Tonix Pharmaceuticals Holding Corp.'s revenue data from 2008 to 2026 shows full historical quarterly detail on this page.
How is TNXP's revenue distributed by segment?
TNXP reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does TNXP's revenue compare to industry peers?
Tonix Pharmaceuticals Holding Corp. (TNXP) with TTM revenue of $18M and +183.2% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.